The Combination of Lanraplenib, a Selective SYK Inhibitor, and Gilteritinib, a FLT3 Inhibitor, Targets Aberrant Proliferation and Differentiation Blockade in Acute Myeloid Leukemia

被引：2
|
作者：
Carvajal, Luis A. [1 ]
McKeown, Michael R. [2 ]
Hood, Tressa [2 ]
Guo, Linlin [2 ]
Lin, Charles Y. [2 ]
DiMartino, Jorge F. [1 ]
机构：
[1] Kronos Bio Inc, San Mateo, CA USA
[2] Kronos Bio Inc, Cambridge, MA USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-186605
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
616
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Discovery of a Diaminopyrimidine FLT3 Inhibitor Active against Acute Myeloid Leukemia
    Jarusiewicz, Jamie A.
    Jeon, Jae Yoon
    Connelly, Michele C.
    Chen, Yizhe
    Yang, Lei
    Baker, Sharyn D.
    Guy, R. Kiplin
    ACS OMEGA, 2017, 2 (05): : 1985 - 2009
  • [22] Glutaminase inhibition improves FLT3 inhibitor therapy for acute myeloid leukemia
    Gregory, Mark A.
    Nemkov, Travis
    Reisz, Julie A.
    Zaberezhnyy, Vadym
    Hansen, Kirk C.
    D'Alessandro, Angelo
    DeGregori, James
    EXPERIMENTAL HEMATOLOGY, 2018, 58 : 52 - 58
  • [23] Gilteritinib in the treatment of relapsed and refractory acute myeloid leukemia with a FLT3 mutation
    Chew, Serena
    Mackey, Melissa C.
    Jabbour, Elias
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2020, 11
  • [24] AMG 925 Is a Dual FLT3/CDK4 Inhibitor with the Potential to Overcome FLT3 Inhibitor Resistance in Acute Myeloid Leukemia
    Li, Cong
    Liu, Liqin
    Liang, Lingming
    Xia, Zhen
    Li, Zhihong
    Wang, Xianghong
    McGee, Lawrence R.
    Newhall, Katie
    Sinclair, Angus
    Kamb, Alexander
    Wickramasinghe, Dineli
    Dai, Kang
    MOLECULAR CANCER THERAPEUTICS, 2015, 14 (02) : 375 - 383
  • [25] Plm-102, a Next Generation FLT3 Inhibitor, Shows Potent Anti-Leukemic Activity on Resistance to Gilteritinib in FLT3 Mutated Acute Myeloid Leukemia
    Lee, Jae-Seon
    Park, Min Ji
    Sun, Ningning
    Park, Jin-Hee
    Oh, Su-jin
    Moon, Miran
    Kim, Myung Jin
    Jang, Soo Yeon
    Kim, Yong-Chul
    BLOOD, 2023, 142
  • [26] Gilteritinib-Based Combination Therapy in Adult Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia
    Chen, Nianci
    Pan, Jiajia
    Zhou, Yile
    Mao, Liping
    Lou, Yinjun
    Qian, Jiejing
    Xu, Gaixiang
    Wei, Juying
    Zhou, De
    Shou, Lihong
    Li, Huang
    Yan, Minchao
    Zeng, Hui
    Fan, Cuihua
    Wu, Gongqiang
    Feng, Weiying
    Tong, Hongyan
    Jin, Jie
    Wang, Huafeng
    BLOOD, 2023, 142
  • [27] Effects of the FLT3 inhibitor PKC 412 in combination with cytostatic drugs in vitro in acute myeloid leukemia.
    Möllgård, L
    Bengtzen, S
    Fioretos, T
    Andersson, A
    Paul, C
    Lehmann, S
    BLOOD, 2004, 104 (11) : 501A - 501A
  • [28] Overcoming therapy resistance in FLT3 wildtype Acute Myeloid Leukemia by a novel venetoclax combination strategy with Gilteritinib
    Schmidt, C.
    Janssen, M.
    Bruch, P. -M
    Rohde, C.
    Herbst, S. A.
    Knoll, M.
    Kolb, C.
    Vierbaum, L.
    Besenbeck, B.
    Blank, M. F.
    Pabst, C.
    Jaramillo, S.
    Schlenk, R. F.
    Baldus, C.
    Bornhaeuser, M.
    Roellig, C.
    Platzbecker, U.
    Serve, H.
    Sauer, T.
    Mueller-Tidow, C.
    Dietrich, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 88 - 88
  • [29] Gilteritinib use in the treatment of relapsed or refractory acute myeloid leukemia with a FLT3 mutation
    Ballesta-Lopez, Octavio
    Solana-Altabella, Antonio
    Megias-Vericat, Juan Eduardo
    Martinez-Cuadron, David
    Montesinos, Pau
    FUTURE ONCOLOGY, 2020, 17 (02) : 215 - 228
  • [30] AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)
    Zarrinkar, Patrick P.
    Gunawardane, Ruwanthi N.
    Cramer, Merryl D.
    Gardner, Michael F.
    Brigham, Daniel
    Belli, Barbara
    Karaman, Mazen W.
    Pratz, Keith W.
    Pallares, Gabriel
    Chao, Qi
    Sprankle, Kelly G.
    Patel, Hitesh K.
    Levis, Mark
    Armstrong, Robert C.
    James, Joyce
    Bhagwat, Shripad S.
    BLOOD, 2009, 114 (14) : 2984 - 2992
12345